Participate in the #LaFAnAttendPas co-innovation program to improve stroke prevention in people affected by Atrial Fibrillation

[ad_1]

To innovate and advance the care of patients with Atrial Fibrillation, the Bristol Myers Squibb – Pfizer Alliance is launching a co-innovation program called #LaFAnAttendPas. Presentation.

Atrial Fibrillation, a public health issue

Today, Atrial Fibrillation is the most common heart rhythm disorder[1]. One in four people over 40 will develop this disease[2]. It affects 1 in 100 people in the general population and almost 70% of patients are over 75 years old[1].

In patients with Atrial Fibrillation, the heart atria no longer contracts effectively, blood stays there longer, and blood clots can form. If the clots travel through the bloodstream, they can travel to an artery in the brain and cause a stroke.

Atrial Fibrillation Increases Stroke Risk 5-fold[3]. The latter is the leading cause of physical disability in adults in France.[4]. Atrial Fibrillation generates a decrease in cardiac output which can cause palpitations, unusual shortness of breath, abnormal fatigue1 and lead to an inability to perform activities of daily living.

Chronic disease, Atrial Fibrillation requires a management over time based on the treatment of the arrhythmia itself and the prevention of blood clots to limit the risk of stroke.

#LaFAnAttendPas: an innovative program to meet the challenges of patient care

To address the issue related to the challenges of managing AF and its impact on public health, Bristol Myers Squibb -Pfizer Alliance launches #LaFAnAttendPas program. The objective is to mobilize the expertise – health professionals, associations of health professionals, representatives of patient associations, designers, start-ups, students from all walks of life, etc. – to provide innovative solutions for patients and caregivers.

For the first season, in May 2021, the chosen theme is “Improving stroke prevention in people affected by Atrial Fibrillation”, in the format of an online innovation sprint that will last 1 month.To respond to this public health issue, 3 challenges are proposed:

1. How to make the announcement of the disease awareness of the risks of AF?

2. How to promote the emergence of a multidisciplinary therapeutic team around the patient in the management of AF?

3. How to support the appropriation and increase in skills of patients?

A community to co-innovate

A group of innovators will help to imagine new solutions to respond to the problems identified:

• Representatives of patient and caregiver associations

• Health professionals: general practitioners, cardiologists, pharmacists, nurses, etc.

• Designers, UX specialists, start-ups …

• Innovators from all walks of life.

A multidisciplinary committee to guide and identify

Composed of 4 colleges (Health professionals, Patient associations, E-health, BMS-Pfizer Alliance), the role of the committee is to:

• Define the criteria making it possible to identify a “good” solution to deploy.

• Identify and classify the solutions resulting from the sprint according to these criteria.

• Determine the evaluation criteria, particularly clinical, of the proposed solutions.

• Encourage the support of solutions (networking, support, experimentation, etc.).

Experts to inspire

To support the participants and share their knowledge and experiences, a group of experts will be present. Their role is to inspire participants and provide the keys to understanding the disease, the issue and the challenges. They will intervene in particular on the following subjects:

• What is Atrial Fibrillation? Causes, mechanism, consequences, epidemiological data… –challenge 1

• Atrial Fibrillation in Current Practice – challenge 2

• Atrial Fibrillation and the Patient Experience – challenge 3

A 3-step sprint

The #FAnAttendPas is a 3-step collective intelligence process co-constructed with designer sessions and a team of sponsors.

• Step 1: inspiration sequenceDiscovery workshops in digital format, led by experts, will be offered to create the conditions of engagement of participants by involving them in researching the issues of AMD issues. The objective is to engage participants in the collaborative innovation process via sequences of inspiration.

• Step 2: construction sequenceThe multidisciplinary committee is mobilized to determine the criteria for a “good” solution to be deployed and the criteria for clinical evaluation of the solutions devised.

• Step 3: ideation sequence & solution – final sprintFor this third phase, which corresponds to the final sprint, creativity workshops in 2 half-days will be deployed: an ideation workshop and a second one to find solutions.

The objective of this final sprint is to bring out new approaches to better prevent the risk of stroke in people affected by Atrial Fibrillation. The sequence is divided into 3 phases:

• An ideation phaseAn extension of the inspiration workshops, this half-day phase (3 hours) will allow the teams to be structured around common issues and to share a common vision within each team.

• A solution phaseThis second time, also of 3 hours, will allow a team solution to emerge, to build it, define it, or even pre-prototype it.

• A selection phaseThe jury selects and classifies the solutions designed by the teams on the basis of the previously defined criteria.

You have until May 3 to register! www.lafanattendpas.com #LaFAnAttendPas.

Post produced in partnership with the Bristol Myers Squibb Alliance – Pfizer

PP-GIP-FRA-2392 – CVFR2100590-01 – NP – April 2021

[1] HAS. Care path guide. Atrial fibrillation. February 2014

[2] Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004 Aug 31; 110 (9): 1042-6. doi: 10.1161 / 01.CIR.0000140263.20897.42. Epub 2004 Aug 16. PMID: 15313941

[3] Camm AJ et al. Guidelines for the management of atrial fibrillation. Eur Heart J. (2010) 31, 2369-2429)

[4] https://www.inserm.com/information-en-sante/dossiers-information/accident-vasulaires-cerebral-avc

Similar articles

[ad_2]